Par Steps In With Chantix Rival After Pfizer Recall
Endo Unit’s Launch Of US Varenicline Tablets Comes After Early Approval
Executive Summary
Endo’s Par generics unit has launched the first US generic version of Pfizer’s Chantix (varenicline) tablets, entering the market just after the originator recalled the brand over nitrosamine impurities.
You may also be interested in...
Stock Watch: Ulterior Motives For Talking Down Pfizer
Pfizer’s pandemic-related windfalls might be prompting some investors and analysts to try steering the resulting largesse towards their own favored acquisition candidates.
Endo Offloads Manufacturing Site To Strides Pharma
Endo enters into an agreement with the subsidiaries of Strides Pharma to sell its manufacturing site in Chestnut Ridge, New York. Meanwhile, the company sees a double-digit drop in its generics business. Furthermore, Endo executes settlement resolving all opioid-related claims in Tennessee.
FDA Looks To Solve Chantix Shortage With Par ANDA Approval
Endo’s Par looks set to provide much needed supply in the US market for varenicline tablets, after originator Pfizer ran into supply and distribution problems due to the presence of a nitrosamine for its Chantix original.